The Infectious Diseases Society of America has developed a multi-pronged plan to combat deadly antibiotic-resistant "super bugs," according to an IDSA news release.
IDSA's new policy paper, "Combating Antimicrobial Resistance: Policy Recommendations to Save Lives," can be accessed here . In its policy paper, IDSA makes the following recommendations:
• Creating incentives and removing economic and regulatory disincentives for antibiotic research and development so companies find developing new antibiotics a viable business endeavor.
• Recalibrating and better communicating the FDA's requirements for new antibiotic approvals.
• Funding antibiotic R&D efforts under the Department of Health and Human Services' Biomedical Advanced Research and Development Authority and proposed independent strategic investment firm.
• Supporting R&D for rapid diagnostic tests to identify the cause of infections more quickly.
• Designating a leader within HHS to facilitate coordination of federal efforts and better utilize outside experts.
• Promoting the judicious use of available antibiotics through better stewardship programs and infection control practices.
• Creating an Antimicrobial Innovation and Conservation Fee to help pay for drug development and stewardship.
• Strengthening public health measures and research that lead to new interventions.
• Establishing non-profit public-private partnerships to invest in bringing new antibiotics to market.
Read the news release about IDSA's recommendations to combat antibiotic-resistant "super bugs."
Read other coverage about antibiotic-resistant "super bugs":
- Dr. Edo McGowan Responds to Study Indicating MRSA Infection May Be Seasonal
- California Department of Health Official Encourage Hospitals to Adopt Antimicrobial Stewardship Programs
- Environmental Cleaning and Disinfection: What Infection Preventionists Need to Know
IDSA's new policy paper, "Combating Antimicrobial Resistance: Policy Recommendations to Save Lives," can be accessed here . In its policy paper, IDSA makes the following recommendations:
• Creating incentives and removing economic and regulatory disincentives for antibiotic research and development so companies find developing new antibiotics a viable business endeavor.
• Recalibrating and better communicating the FDA's requirements for new antibiotic approvals.
• Funding antibiotic R&D efforts under the Department of Health and Human Services' Biomedical Advanced Research and Development Authority and proposed independent strategic investment firm.
• Supporting R&D for rapid diagnostic tests to identify the cause of infections more quickly.
• Designating a leader within HHS to facilitate coordination of federal efforts and better utilize outside experts.
• Promoting the judicious use of available antibiotics through better stewardship programs and infection control practices.
• Creating an Antimicrobial Innovation and Conservation Fee to help pay for drug development and stewardship.
• Strengthening public health measures and research that lead to new interventions.
• Establishing non-profit public-private partnerships to invest in bringing new antibiotics to market.
Read the news release about IDSA's recommendations to combat antibiotic-resistant "super bugs."
Read other coverage about antibiotic-resistant "super bugs":
- Dr. Edo McGowan Responds to Study Indicating MRSA Infection May Be Seasonal
- California Department of Health Official Encourage Hospitals to Adopt Antimicrobial Stewardship Programs
- Environmental Cleaning and Disinfection: What Infection Preventionists Need to Know
